Real-World Safety of Vedolizumab in Inflammatory Bowel Disease: A Retrospective Cohort Study Supported by FAERS Signal Analysis.

Pharmaceuticals (Basel) · 2025 · PMC12389730 · PMID 40872519

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In the GEMINI trials and a subsequent pooled analysis, the incidence of URTIs was numerically higher in the vedolizumab group compared to placebo, although this difference did not reach statistical significance [ 18 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.